<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CAR-T cell therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/car-t-cell-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Jan 2026 12:29:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CAR-T cell therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>CAR T Cell Therapy’s Critical Role in Young Cancer Patients</title>
		<link>https://bioengineer.org/car-t-cell-therapys-critical-role-in-young-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 12:28:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CD19-targeted immunotherapy]]></category>
		<category><![CDATA[çocuklarda CAR T hücre tedavisi]]></category>
		<category><![CDATA[immunotherapy challenges]]></category>
		<category><![CDATA[İşte içerik için 5 uygun etiket (virgülle ayrılmış): **pediatrik kanser immünoterapisi]]></category>
		<category><![CDATA[Pediatric Oncology]]></category>
		<category><![CDATA[pediatrik CAR T erişimi** **Açıklama:** 1. **pediatrik kanser]]></category>
		<category><![CDATA[solid tümörlerde CAR T zorlukları]]></category>
		<category><![CDATA[tisagenlecleucel]]></category>
		<category><![CDATA[young cancer patients]]></category>
		<guid isPermaLink="false">https://bioengineer.org/car-t-cell-therapys-critical-role-in-young-cancer-patients/</guid>

					<description><![CDATA[Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary approach in the treatment of hematologic malignancies, particularly in pediatric patients with B cell acute lymphoblastic leukemia (B-ALL). The journey from early clinical successes to the landmark FDA approval of tisagenlecleucel, the first gene therapy approved for this indication, has been marked by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319779</post-id>	</item>
		<item>
		<title>Dextran Nanoparticles Boost CAR T Cell Production</title>
		<link>https://bioengineer.org/dextran-nanoparticles-boost-car-t-cell-production/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 06:50:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[and impact: **Dextran nanoparticles]]></category>
		<category><![CDATA[application]]></category>
		<category><![CDATA[Based on the content]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[CAR T cell manufacturing]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[dextran nanoparticles]]></category>
		<category><![CDATA[focusing on the core technology]]></category>
		<category><![CDATA[here are 5 suitable tags]]></category>
		<category><![CDATA[scalable manufacturing]]></category>
		<category><![CDATA[T-cell expansion]]></category>
		<guid isPermaLink="false">https://bioengineer.org/dextran-nanoparticles-boost-car-t-cell-production/</guid>

					<description><![CDATA[In a groundbreaking advance that could redefine the landscape of cancer immunotherapy, researchers have unveiled a novel dextran-based nanoparticle platform designed to revolutionize the manufacturing process of CAR T cells. This pioneering technology promises to significantly enhance the efficacy and scalability of CAR T-cell therapies, which have already demonstrated remarkable success in treating hematological malignancies [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318774</post-id>	</item>
		<item>
		<title>Harnessing CAR T-Cells for Chronic Viral Infections</title>
		<link>https://bioengineer.org/harnessing-car-t-cells-for-chronic-viral-infections/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 Jan 2026 16:51:23 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[chronic viral infections]]></category>
		<category><![CDATA[immune evasion]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[translational medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/harnessing-car-t-cells-for-chronic-viral-infections/</guid>

					<description><![CDATA[Chimeric Antigen Receptor T-Cell Therapy: A Revolutionary Approach to Chronic Viral Infections Chronic viral infections pose significant challenges to global health, affecting millions of individuals worldwide. Despite advancements in antiviral therapies, many patients experience persistent viral replication and chronic disease due to the virus’s ability to evade the immune system. In recent years, immunotherapy, and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316887</post-id>	</item>
		<item>
		<title>From Bloodstream to Solid Tumors: A Breakthrough Boost for CAR T Cell Therapy</title>
		<link>https://bioengineer.org/from-bloodstream-to-solid-tumors-a-breakthrough-boost-for-car-t-cell-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 03 Nov 2025 18:26:00 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR T cell therapy for solid tumors]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CRISPR gene editing advancements]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[Immune checkpoint inhibitors]]></category>
		<category><![CDATA[Intracellular immune checkpoint targeting]]></category>
		<category><![CDATA[PTPN2 inhibition]]></category>
		<category><![CDATA[PTPN2 inhibition in immunotherapy]]></category>
		<category><![CDATA[solid tumor immunotherapy]]></category>
		<category><![CDATA[T cell memory enhancement]]></category>
		<guid isPermaLink="false">https://bioengineer.org/from-bloodstream-to-solid-tumors-a-breakthrough-boost-for-car-t-cell-therapy/</guid>

					<description><![CDATA[Chimeric Antigen Receptor (CAR) T cell therapies have heralded a new era in oncological treatment, yielding transformative outcomes particularly in hematologic malignancies. These immunotherapies engineer patients’ own T cells to express synthetic receptors that selectively recognize and eradicate cancerous cells in the bloodstream. However, despite their spectacular success against blood cancers, CAR T cells have [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">290665</post-id>	</item>
		<item>
		<title>Revolutionizing AML: CAR-T and CAR-NK Cell Therapies</title>
		<link>https://bioengineer.org/revolutionizing-aml-car-t-and-car-nk-cell-therapies/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 25 Oct 2025 21:22:17 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Acute myeloid leukemia (AML)]]></category>
		<category><![CDATA[CAR-NK cell therapy]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revolutionizing-aml-car-t-and-car-nk-cell-therapies/</guid>

					<description><![CDATA[In recent years, the application of immunotherapy in the treatment of acute myeloid leukemia (AML) has garnered increasing attention within the scientific community. Among the most promising advancements in this realm are the development and application of Chimeric Antigen Receptor T-cell (CAR-T) and Natural Killer (NK) cell therapies. A recent study led by researchers Wu, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">286884</post-id>	</item>
		<item>
		<title>Safe Epigenetic Reprogramming Enables Simultaneous Multi-Gene Editing in T Cells for Enhanced CAR-T Therapies</title>
		<link>https://bioengineer.org/safe-epigenetic-reprogramming-enables-simultaneous-multi-gene-editing-in-t-cells-for-enhanced-car-t-therapies/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 21 Oct 2025 09:25:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CRISPRoff technology]]></category>
		<category><![CDATA[Epigenetic reprogramming]]></category>
		<category><![CDATA[multiplex gene editing]]></category>
		<category><![CDATA[solid tumor immunotherapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/safe-epigenetic-reprogramming-enables-simultaneous-multi-gene-editing-in-t-cells-for-enhanced-car-t-therapies/</guid>

					<description><![CDATA[In a stunning leap forward for immunotherapy, researchers from the Arc Institute, Gladstone Institutes, and the University of California, San Francisco have unveiled a groundbreaking epigenetic editing platform that redefines the genetic programming of human T cells. Published in the prestigious journal Nature Biotechnology on October 21, 2025, this innovative approach combines cutting-edge CRISPR technologies—dubbed [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">284237</post-id>	</item>
		<item>
		<title>Enhancing the Body’s Natural Defenses Against Cancer</title>
		<link>https://bioengineer.org/enhancing-the-bodys-natural-defenses-against-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 24 Sep 2025 16:32:59 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[Genetic engineering]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/enhancing-the-bodys-natural-defenses-against-cancer/</guid>

					<description><![CDATA[In a groundbreaking advancement in the field of cancer treatment, researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna have introduced a highly innovative platform designed to enhance the efficacy of CAR T cell therapy. This development addresses the limitations associated with traditional [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">271812</post-id>	</item>
		<item>
		<title>Genetic Screening Advances Boost CAR-T Therapy Effectiveness Against Multiple Myeloma and Other Cancers</title>
		<link>https://bioengineer.org/genetic-screening-advances-boost-car-t-therapy-effectiveness-against-multiple-myeloma-and-other-cancers/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 24 Sep 2025 15:42:46 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[in vivo CRISPR screening]]></category>
		<category><![CDATA[multiple myeloma]]></category>
		<guid isPermaLink="false">https://bioengineer.org/genetic-screening-advances-boost-car-t-therapy-effectiveness-against-multiple-myeloma-and-other-cancers/</guid>

					<description><![CDATA[In a groundbreaking advance that could redefine the future of cancer immunotherapy, researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have harnessed the power of CRISPR gene-editing technology to optimize chimeric antigen receptor (CAR)-T cell therapies against multiple myeloma. This innovative study, recently published in Nature, unveils how systematic genetic [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">271783</post-id>	</item>
		<item>
		<title>CAR T-Cell and TIL Therapies in GI Cancers</title>
		<link>https://bioengineer.org/car-t-cell-and-til-therapies-in-gi-cancers/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 20 Sep 2025 07:34:18 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[Clinical oncology research]]></category>
		<category><![CDATA[Gastrointestinal malignancies]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[Tumor-infiltrating lymphocytes (TILs)]]></category>
		<guid isPermaLink="false">https://bioengineer.org/car-t-cell-and-til-therapies-in-gi-cancers/</guid>

					<description><![CDATA[In the relentless battle against gastrointestinal malignancies, immunotherapy has emerged as a beacon of hope, transforming once grim prognoses into stories of resilience and recovery. Among the most promising advances are the therapies involving chimeric antigen receptor T-cells (CAR T-cells) and tumor-infiltrating lymphocytes (TILs). A newly published comprehensive review by Sayed et al. in Medical [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">270905</post-id>	</item>
		<item>
		<title>CAR T-Cell Therapy: The Future of Cancer Eradication</title>
		<link>https://bioengineer.org/car-t-cell-therapy-the-future-of-cancer-eradication/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 06 Aug 2025 20:38:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Treatment Innovations]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[Genetic Engineering in Medicine]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[precision oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/car-t-cell-therapy-the-future-of-cancer-eradication/</guid>

					<description><![CDATA[In recent years, the revolutionary field of immunotherapy has drastically reshaped the landscape of cancer treatment, pushing the boundaries of what modern medicine can achieve. Among these advancements, Chimeric Antigen Receptor (CAR) T-cell therapy stands out as one of the most promising strategies that could redefine the future of cancer eradication. Building upon decades of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">254096</post-id>	</item>
		<item>
		<title>‘Leukemia-on-a-Chip’ Innovation Set to Revolutionize CAR T Cell Therapy for Blood Cancer</title>
		<link>https://bioengineer.org/leukemia-on-a-chip-innovation-set-to-revolutionize-car-t-cell-therapy-for-blood-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 02 Jul 2025 04:37:48 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[3D cell culture technology]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[leukemia-on-a-chip]]></category>
		<category><![CDATA[personalized cancer treatment]]></category>
		<category><![CDATA[preclinical cancer models]]></category>
		<guid isPermaLink="false">https://bioengineer.org/leukemia-on-a-chip-innovation-set-to-revolutionize-car-t-cell-therapy-for-blood-cancer/</guid>

					<description><![CDATA[In a groundbreaking fusion of bioengineering and immunology, researchers from the University of Pennsylvania’s Perelman School of Medicine and New York University’s Tandon School of Engineering have unveiled a miniature yet powerful laboratory device poised to revolutionize the future of blood cancer treatment. This “leukemia-on-a-chip” innovation promises to dramatically enhance the way chimeric antigen receptor [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">251059</post-id>	</item>
		<item>
		<title>Fighting Osimertinib Resistance in Lung Cancer Treatment</title>
		<link>https://bioengineer.org/fighting-osimertinib-resistance-in-lung-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Nov 2023 18:43:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[brigatinib]]></category>
		<category><![CDATA[C797S mutation]]></category>
		<category><![CDATA[C797S/T790M mutations]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[clinical studies]]></category>
		<category><![CDATA[EGFR amplification]]></category>
		<category><![CDATA[EGFR exon 18 mutations]]></category>
		<category><![CDATA[EGFR exon 20 mutations]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[EGFR-TKI]]></category>
		<category><![CDATA[fourth generation TKI]]></category>
		<category><![CDATA[health research]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[innovations in cancer treatment]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[molecular treatment methods]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[ORCHARD trial]]></category>
		<category><![CDATA[osimertinib resistance]]></category>
		<category><![CDATA[osimertinib treatment]]></category>
		<category><![CDATA[PD-1]]></category>
		<category><![CDATA[PD-L1]]></category>
		<category><![CDATA[targeted cancer therapy]]></category>
		<category><![CDATA[tyrosine kinase inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=217045</guid>

					<description><![CDATA[Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Among its types, non-small cell lung cancer (NSCLC) constitutes approximately 85%, posing significant challenges for patients and healthcare professionals, especially due to its late-stage diagnosis and complex treatment processes. However, the last decade has witnessed transformative advancements in molecular biology and drug development, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">217045</post-id>	</item>
	</channel>
</rss>
